Educational Tools for your Clinical Practice

• Allergy & Immunology
• Cardiology
• Dermatology
• Endocrinology
• Family Practice/Internal Medicine
• Gastroenterology
• Hematology-Oncology
• Infectious Disease
• Neurology
• Obesity
• Ophthalmology
• Orthopedics
• Pediatrics
• Pharmacy
• Psychiatry
• Pulmonology
• Rheumatology

Allergy & Immunology

Asthma

• 2020 GINA Report, Global Strategy for Asthma Management and Prevention
• Global Initiative for Asthma: Pocket Guide ForAsthma Management And Prevention (Updated 2020)
• American Lung Association: Severe Asthma
• Biological treatments for severe asthma: A major advance in asthma care
• Advances and recent developments in asthma in 2020
• Asthma biologics: Comparing trial designs, patient cohorts and study results
• Anti-IL5 therapies for asthma
• Mepolizumab Prescribing Information
• Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study
• Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype
• Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis
• Usability of mepolizumab single-use prefilled syringe for patient self-administration
• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
• 2019 GINA Report, Global Strategy for Asthma Management and Prevention
• Global Initiative for Asthma: Pocket Guide For Asthma Management And Prevention (Updated 2019)
• National Jewish Health Inhaler Instructional Videos

Chronic Idiopathic Urticaria

• EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
• XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
• The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU
• A Comparison of the United States and International Perspective on Chronic Urticaria Guidelines
• Patient education: Hives (urticaria) (Beyond the Basics)
• Joint Task Force Guidelines: The diagnosis and management of acute and chronic urticaria: 2014 update
• Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
• Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study
• Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study

Food Allergy

• Peanut Allergy – Information for Patients
• The Current State of Oral Immunotherapy – Information from the American Academy of Allergy Asthma & Immunology
• AR101 Oral Immunotherapy for Peanut Allergy
• The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States
• NIAID Addendum Guidelines for the Prevention of Peanut Allergy in the United States
• Food allergen immunotherapy: Current status and prospects for the future
• What is new in managing patients with food allergy? Almost everything.
• The Prevalence and Natural History of Food Allergy
• Quantitative Assessment of the Safety Benefits Associated with Increasing Clinical Peanut Thresholds Through Immunotherapy

Cardiology

Acute Coronary Syndrome

• IMPROVE-IT Trial: ACC 2015
• 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
• Heart Disease - Patients’ Educational Tool
• Diabetes Optimal Care Cardiovascular Risk Reduction (DOC-CARE) EHR “MY CHART”
• Guidelines Recommendations on the Use of Platelet Function and Genetic Testing

Atherothrombosis

• 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
• Coagulation factor Xa (recombinant), inactivated-zhzo
• Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
• Management of bleeding in patients receiving direct oral anticoagulants
• Resources to support Joint Commission Accredited organizations implementation of: Reduce the likelihood of patient harm associated with the use of anticoagulant therapy
• Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
• Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
• Selection of a suitable patient population for new antiplatelet therapy from the large clinical trial database of the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-thrombolysis in myocardial infarction 50 (TRA-2P-TIMI50) trial.
• Current APT Recommendations for Longterm Secondary Prevention
• DAPT PEGASUS and TRA 2P Trials Primary Efficacy and Safety Outcomes

Cardiac Imaging

• Cardiac Stress Testing: Choosing the Right Test and When

Dyslipidemia

• Bempedoic Acid for LDL-C Lowering: What Do We Know?
• Heart Disease and Stroke Statistics—2021 Update
• Identification of female-specific risk enhancers throughout the lifespan of women to improve CVD prevention
• The ABCs of Primary Cardiovascular Prevention: 2019 Update
• Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
• Improving the Cardiovascular Health of Women in the Nation
• Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
• Epidemiology of Dyslipidemia and Economic Burden on the Healthcare System
• Prescribing Information for Alirocumab
• Prescribing Information for Evolocumab
• Diabetic Dyslipidemia: Causes and Consequences
• 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
• ACC Statin Intolerance Tool
• 2017 NLA Expert Panel on Treatment with PCSK9 Inhibitors
• 2017 NLA Expert Panel on Treatment with PCSK9 Inhibitors - Infographic
• PCSK9 Inhibitor Access Barriers – Issues and Recommendations
• Current Indications, Cost, and Clinical Use of Anti-PCSK9 Monoclonal Antibodies
• NLA Recommendations for Patient-Centered Management of Dyslipidemia
• Patient Information: Reduce Your Risk of Heart Attack and Stroke
• High Cholesterol Educational Materials for Patients

Familial Chylomicronemia Syndrome (FCS)

• Burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study
• Understanding FCS – for Patients
• About FCS
• 2015-2020 Dietary Guidelines
• Medications that Increase Triglycerides
• FCS References
• What is FCS?

Familial Hypercholesterolemia

• Learning About Familial Hypercholesterolemia

Heart Failure

• Frequently Asked Questions About Heart Failure – for Patients
• PARADIGM-HF Trial of Sacubitril/Valsartan
• Ivabradine in Heart Failure
• A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock
• Cardiac Calcitropes, Myotropes, and Mitotropes
• Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials
• Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
• Heart Failure: Patient Education

Hypertension

• 2017 Guideline for High Blood Pressure in Adults
• High Blood Pressure Information for Patients
• Treatment of resistant hypertension
• CDC High Blood Pressure Fact Sheet
• Million Hearts® Hypertension Control: Action Steps for Clinicians
• Systolic Blood Pressure Intervention Trial (SPRINT)

Hypertriglyceridemia

• Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
• National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
• Infographic: Use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
• REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. AHA 2018.
• Hypertriglyceridemia and atherosclerosis
• Hypertriglyceridemia and omega-3 fatty acids: Their often-overlooked role in cardiovascular disease prevention
• Fish and Omega-3 Fatty Acids

Venous Thromboembolism

• What is Venous Thromboembolism?
• Antithrombotic Therapy for VTE Disease
• Wells’ Criteria for Pulmonary Embolism

Dermatology

Facial Aesthetics

• The Anatomy of the Aging Face
• FDA approval for Restylane Contour for cheek augmentation and correction of midface contour deficiencies

Pemphigus Vulgaris

• Pemphigus Vulgaris
• FDA approves Rituxan for pemphigus vulgaris

Psoriasis

• An Overview of PsO and PsA – For Patients
• Systemic PsO and PsA Medications – For Patients
• Topical Treatments for Psoriasis – For Patients
• The Parent/Caregiver Guide to Psoriasis – For Patients
• Phototherapy for Psoriasis – For Patients
• Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis
• Psoriasis Clinical Guideline from the American Academy of Dermatology
• National Psoriasis Foundation
• Psoriasis – Children’s Educational Picture Book
• Psoriasis Q & A – For Patients
• Questions to Ask Your Clinician about Psoriasis - Patient Handout

Endocrinology

Diabetes

• Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
• New Decade, New FDA Guidance for Diabetes Drug Development
• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
• 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
• ESC Prevention Guideline 2021Algorithm for Patients With T2DM
• AACE Diabetes Resource Center
• Diabetic Retinopathy: A Position Statement by the ADA
• Accurate Insulin Decisions – For Doctors
• Best content from AFP—Diabetes: Type 2
• Family Practice Management Toolbox: Diabetes
• Diabetes and You: All Medicines Matter!
• Mealtime Insulin Management
• Advanced Insulin Management: Using Insulin-to-Carb Ratios and Correction Factors
• 4 Steps to Manage Your Diabetes for Life
• Managing Your Blood Sugar - Patient Handout
• Diabetic Macular Edema - What You Need To Know - Patient Handout
• Living with Diabetes

Acromegaly

• Acromegaly: An Endocrine Society Clinical Practice Guideline
• American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update
• Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
• Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial
• Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
• Acromegaly: Patient Information

Osteoporosis

• AACE/ACE 2016 Postmenopausal Osteoporosis Treatment Guidelines
  
• Overview of the management of osteoporosis in postmenopausal women
  
• Clinician’s Guide to the Prevention and Treatment of Osteoporosi
• New Insights into Treatment of Osteoporosis in Postmenopausal Women
  
• NIH Handout on Health: Osteoporosis - Patient Handout
  

Family Practice/Internal Medicine

Chronic Cough

• American Lung Association: Chronic Cough Resources and Videos
• Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report
• European Respiratory Society Guidelines on the Diagnosis and Treatment of Chronic Cough in Adults and Children
• Translational review: Neuroimmune mechanisms in cough and emerging therapeutic targets
• Management of chronic refractory cough in adults
• Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
• The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study
• P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough

Pain Management

• CDC Guideline for Prescribing Opioids for Chronic Pain— United States, 2016

Peyronie’s Disease

• Peyronie’s Disease
• Peyronie’s disease: new paradigm for the treatment of a unique cause of erectile dysfunction

Substance Use Disorders

• Sublocade Prescribing Information
• Medication Assisted Treatment (MAT) Certification
• Substance Abuse & Mental Health Services Administration (SAMHSA) supported CME courses on prescribing opioids for chronic pain from AAAP, AOAAM, ASPMNDPT, ATTC and ASAM

Gastroenterology

Biosimilars

• Biosimilars - What IBD Patients Should Know
• Biosimilar Patient and Prescriber Outreach Materials
• Biosimilar Development, Review, and Approval
• Biosimilars Basics infographic for Patients
• What is a Biosimilar?
• Prescribing Biosimilar Products
• Biosimilar Development Process

Cirrhosis

• Cirrhosis
• Hepatic Encephalopathy

Eosinophilic Esophagitis (EoE)

• Pathophysiology of Eosinophilic Esophagitis
• Environmental Factors and Eosinophilic Esophagitis
• International Consensus Diagnostic Criteria for Eosinophilic Esophagitis
• Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis
• Treatment of Eosinophilic Esophagitis: Clinical Decision Support Tool
• Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis in Adolescents and Adults: Results From a Phase 3, Randomized, Placebo-Controlled Trial

Hepatitis C Virus (HCV)

• HCV Next
• American Gastroenterological Association Hepatitis C Resources
• Direct-Acting Antivirals: Side Effects Management Handouts
• CDC Hepatitis C Resource Center
• Patient-Reported Outcomes for Patients With Chronic Liver Disease
• U.S. Department of Veterans Affairs: Hepatitis C Resources for Healthcare Professionals and Patients
Direct-Acting Antivirals: Side Effects Management Handouts
• Hepatitis C Guidance 2019 Update: AASLD‐IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Hepatitis B Virus (HBV)

• Serologic Test Results
• Testing Asian Americans and Pacific Islanders
• Hepatitis B Are You At Risk - Patient Handout
• CDC Hepatitis B Resource Center

Inflammatory Bowel Disease

• Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
• A Role for Primary Care Pharmacists in the Management of Inflammatory Bowel Disease? Lessons from Chronic Disease: A Systematic Review
• Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn’s Disease and Ulcerative Colitis
• Shared Decision Making in Gastroenterology:Challenges and Opportunities
• Treatment Approaches in IBD: Shared Decision-Making
• Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19
• Coronavirus and IBD Reporting Database
• An Overview of Novel and Emerging Therapies for Inflammatory Bowel Disease
• Understanding IBD Medications and Side Effects (Patient Handout)
• Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
• Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances
• Emotional Well-being Questionnaire – A Patient/Provider Communication Aid
• Which IBD Medication is Right for Me?
• Vedolizumab Prescribing Information
• IBD Checklist for Monitoring & Prevention
• IBD Checklist for Care Continuity
• Ostomates Food Reference Chart
• Ostomy Resources
• Patient Handout: Types of Medications for Crohn's Disease and Ulcerative Colitis
• Signs, Symptoms and Causes of Ulcerative Colitis
• Understanding Ulcerative Colitis - Patient Handout
• Questions to ask your Doctor - Patient Handout
• ACG Clinical Guideline - Ulcerative colitis in Adults
• The Development of Patient-Reported Outcome Measures in Inflammatory Bowel Disease
• Emerging Therapies for Inflammatory Bowel Disease
• ACG Clinical Guideline: Management of Crohn's Disease in Adults
• AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
• Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program
• Emerging therapies for the treatment of ulcerative colitis
• A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review

Lysosomal Acid Lipase Deficiency (LAL-D)

• LAL-D: An under-recognized cause of dyslipidaemia and liver dysfunction
• LAL-D: Getting Tested

Non-Alcoholic Fatty Liver Disease (NAFLD)

• Diagnosis and Management of Non-alcoholic Fatty Liver Disease
• From NAFLD in Clinical Practice to Answers From Guidelines
• NAFLD: Differential Diagnosis – Summary
• NAFLD: Overview of Screening Methods in Children
• NIH Genetic and Rare Diseases Information Center: Lysosomal acid lipase deficiency
• The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the AASLD

Hematology-Oncology

Biosimilars

• FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
• Biosimilar Product Information
• Prescribing Biosimilar and Interchangeable Products

Bladder Cancer

• Immunotherapy for Bladder Cancer – American Cancer Society
• Bladder Cancer - Nation Cancer Institute - For Patients
• Bladder Cancer - Nation Cancer Institute - For Providers

Breast Cancer

• Breast Cancer Treatment – Patient Information
• National Cancer Institute: Breast (Patient Version)
• National Cancer Institute: Breast (Health Professional Version)
• Alternative Screening for Dense Breasts: MRI
• Supplemental MRI Screening for Women with Extremely Dense Breast Tissue
• Ultra-fast detection of breast density using MRT helps determine breast cancer risks
• Techniques for Performing Abbreviated Breast Magnetic Resonance Imaging in Abbreviated MRI of the Breast
• American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
• American Society of Clinical Oncology Breast Cancer Guidelines

Colorectal Cancer

• ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer
• ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
• Screening for Colorectal Cancer US Preventive Services Task Force Recommendation Statement
• BASIC (BLI Adenoma Serrated International Classification) classification for colorectal polyp characterization with blue light imaging
• The adenoma miss rate of blue-laser imaging vs. white-light imaging during colonoscopy
• Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G).
• Adenoma detection rate: in search of quality improvement, not just measurement
• Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology
• Genetic/Familial High-Risk Assessment: Colorectal v3.2017
• Microsatellite Instability - Defective DNA Mismatch Repair: ESMO Biomarker Factsheet
• DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics
• Get Tested for Colon Cancer [video for patients]
• National Cancer Institute: Colorectal Cancer [patient version]
• National Cancer Institute: Colorectal Cancer [health professional version]
• National Cancer Institute: Drugs Approved for Colon and Rectal Cancer
• American Society of Clinical Oncology Gastrointestinal Cancer Guidelines

General Hematology/Oncology

• Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
• NCCN Clinical Practice Guidelines in Oncology
• NCCN Guidelines for Patients
• American Society of Clinical Oncology Supportive Care and Treatment Related Issues
• Increasing Cancer Screening Rates in Primary Care
• A blueprint for cancer screening and early detection: Advancing screening’s contribution to cancer control
• Detection and localization of surgically resectable cancers with a multi-analyte blood test
• Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
• Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
• CDC Recommended Screening Tests for Cancer
• USPSTF Lung Cancer Screening Recommendations: 2021 Updates
• American Cancer Society Guidelines for the Early Detection of Cancer
• American Cancer Society guideline for diet and physical activity for cancer prevention

Head and Neck Cancer

• The value of immunotherapy in head and neck cancer
• Blue Laser Imaging-Bright Improves Endoscopic Recognition of Superficial Esophageal Squamous Cell Carcinoma
• Molecular Interactions and Expression of PD-1 and PD-L1
• Checkpoint Inhibitors Targeting PD-1 vs PD-L1

Hematologic Malignancies

• Multiple Myeloma Disease Overview
• Multiple Myeloma – Treatment Overview for Patients and Caregivers
• Stem Cell Transplantation for Multiple Myeloma – for Patients
• Treatment for Multiple Myeloma – for Health Professionals
• National Cancer Institute: Leukemia (Patient Version)
  
• National Cancer Institute: Leukemia (Health Professional Version)
• National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Patient Version)
• National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Health Professional Version)
• NCCN CLL Guidelines for Patients
• NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019
• Chronic Lymphocytic Leukemia (CLL) for patients and caregivers
• NCCN CLL Guidelines for Patients
• Rai and Binet Systems for Clinical Staging of CLL
• Leukemia & Lymphoma Society Patient Information Booklets
• American Society of Clinical Oncology Hematologic Malignancies Guidelines
• Multiple Myeloma Research Foundation Patient Resources
• Dermatologic Clinics. Cutaneous Lymphoma
• Primary Cutaneous Lymphomas: ESMO Clinical Practice Guidelines
• Clinical pharmacists' contributions to hematopoietic stem cell transplantation: A systematic review.
• The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group.
• It Takes a Village (of Therapies) to Achieve Optimal Long-Term Outcomes for Multiple Myeloma

Hemophilia

• World Federation of Hemophilia Guidelines for the Management of Hemophilia
• Centers for Disease Control and Prevention: Hemophilia Homepage
• National Hemophilia Foundation: Hemophilia A
• World Federation of Hemophilia: Guidelines for the Management of Hemophilia, 3rd Edition
• Emicizumab Prophylaxis in Hemophilia A with Inhibitors
• Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
• New therapies for hemophilia

Hepatocellular carcinoma

• Hepatocellular Carcinoma: ESMO-ESDO Clinical Practice Guidelines
• National Cancer Institute: Liver and Bile Duct Cancers (Patient Version)
• National Cancer Institute: Liver and Bile Duct Cancers (Health Professional Version)
• NCCN Guidelines for Patients: Hepatobiliary Cancers

Kidney Cancer

• Kidney Cancer - American Cancer Society
• Kidney Cancer - NIH - Patient Resources

Lung Cancer

• National Cancer Institute: Lung Cancer (Patient Version)
• National Cancer Institute: Lung Cancer (Health Professional Version)
• Article: NCCN Guidelines Insights: Malignant Pleural Mesothelioma
• Biomarker discussion in National Comprehensive Cancer Network (NCCN) Quick Guide for Lung Cancer
• National Comprehensive Cancer Network (NCCN) Guidelines for Treatment of Cancer by Site
• Patients Educational Tool ─ Lung Cancer: Frequently Asked Questions
• Lung Cancer Screening Guidelines and Recommendations
• Questions to Ask Your Doctor: Non-Small Cell Lung Cancer - Patient Handout
• Understanding Non-Small Cell Lung Cancer - Patient Handout
• How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
• IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

Melanoma

• Melanoma Treatment – for health professionals
• Melanoma Risk Assessment Tool
• Combination Therapy: Nivolumab + Ipilimumab
• Immunotherapy for Melanoma Skin Cancer
• Targeted Therapy for Melanoma
• The Skin Cancer Foundation: Skin Cancer 101 for Patients
• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
• Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Myelodysplastic Syndromes

• About Myelodysplastic Syndromes (MDS)
• Detailed Guide on MDS
• How are myelodysplastic syndromes staged?
• Treating MDS Toolkit
• The Diagnostic Spectrum of MDS, MDS/MPN, and MF Reference Card
• What is MDS? iPad App

Ovarian Cancer

• National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Patient Version)
• National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Health Professional Version)

Infectious Disease

CMV

• Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
• Cytomegalovirus (CMV) Infection
• About CMV for Patients
• Clinical manifestations, diagnosis, and management of CMV disease in kidney transplant recipients
• Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
• Maribavir for Treatment of CVM Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic SCT or SOT Recipients

Coronavirus (COVID-19)

• Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
• Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
• NIH: Therapeutic Management of Hospitalized Adults With COVID-19
• NIH COVID-10 Treatment Guidelines
• FDA COVID-19 Emergency Use Authorizations: Drug and Biological Therapeutic Products
• Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (ACTT-2)
• Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER)
• Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
• Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY)
• COVID-19: immunopathology, pathophysiological mechanisms, and treatment options
• Cytokine storm and the prospects for immunotherapy with COVID-19
• CDC Coronavirus Disease 2019 (COVID-19) Resources
• WHO Resources: COVID-19 Pandemic

HIV

• Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
• Adherence to the Continuum of Care
• Drug-Drug Interactions
• Drug Database: Cabotegravir
• Women with HIV
• Adverse Effects of Antiretroviral Therapy
• Considerations for Antiretroviral Therapy in the Older Patient
• Stanford University HIV Drug Resistance Database
• Understanding HIV Laboratory Tests – for Patients
• HIV and Drug-Resistance Laboratory Testing
• NNRTI Drug Interactions
• NRTI Drug Interactions
• INSTI Drug Interactions
• PI Drug Interactions
• Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Tables
• What to Start: Selecting a First HIV Regimen
• Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
• Opportunistic Infections
• ViiV, J&J's Cabenuva gains FDA approval as long-acting regimen for HIV

Influenza

• Recommendations for Preventionand Control of Influenza inChildren, 2020–2021
• A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season - ScienceDirect
• Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
• Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
• Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
• Baloxavir Prescribing Information
• 2018 Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza
• Seasonal Influenza Vaccine Effectiveness Studies
• Influenza Antiviral Medications: Summary for Clinicians
• FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses
• Information for Clinicians on Influenza Virus Testing
• What You Should Know About Influenza (Flu) Antiviral Drugs
• Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction
• Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
• People at High Risk For Flu Complications
• Clinical Outcomes of Oseltamivir vs. Baloxavir in Patients Hospitalized with Influenza A
• Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children
• Early Treatment With Baloxavir Marboxil in High-Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE-2): A Randomised, Placebo-controlled, Phase 3 Trial
• Similarities and Differences between Flu and COVID-19

Invasive Fungal Infections

• Information for Healthcare Professionals about Invasive Candidiasis
• Information for Healthcare Professionals about Mucormycosis
• Information for Healthcare Professionals about Aspergillosis
• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
• Isavuconazonium sulfate Prescribing Information
• New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies

Molecular Diagnostics

• A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology
• Panels and Syndromic Testing in Clinical Microbiology
• Syndromic Panel-Based Testing in Clinical Microbiology
• New and novel rapid diagnostics that are impacting infection prevention and antimicrobial stewardship
• Advances in rapid diagnostics for bloodstream infections
• Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis
• Relationship of Multiplex Molecular Pneumonia Panel Results With Hospital Outcomes and Clinical Variables
• Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

Pediatrics

• Cryptosporidiosis
• Giardiasis
• Swimming Pool Hygiene
• Facts About Crypto and Swimming Pools - Patient Handout
• Human Papillomavirus (HPV): The Need to Immunize - Patient Handout

Vaccinations

• Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
• Efficacy and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
• Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
• Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
• CDC: Shingles Vaccine Factsheet for Adult Patients
• CDC: Shingles Vaccine Factsheet for Health Care Professionals

Neurology

Alzheimer’s Disease

• Alzheimer’s Disease Fact Sheet
• 2020 Alzheimer’s disease facts and figures
• NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
• Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
• Alzheimer’s disease drug development pipeline: 2020
• Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data

Amyotrophic Lateral Sclerosis

• Amyotrophic Lateral Sclerosis Fact Sheet
• Edaravone Prescribing Information
• ALS Association

Parkinson's Disease

• Parkinson’s Disease Fact Sheet
• The On-Off Phenomenon
• On-Off Phenomenon: When Levodopa Stops Working as Well

Muscular Dystrophy

• Limb-girdle muscular dystrophy
• Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion

Multiple Sclerosis (MS)

• Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis
• Shared decision-making in multiple sclerosis
• Shared Decision-Making in Multiple Sclerosis Management
• The SHARE Approach: Essential Steps of Shared Decision making: Expanded Reference Guide with Sample Conversation Starters
• Guidelines of the Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS
• Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
• The Use of Disease-Modifying Therapies in MS
• Adherence — Patient Information
• Resources for You and Your Practice
• Mobile Applications for People with Multiple Sclerosis (MS)
• Coronavirus (COVID-19)
• COVID-19 advice for people with MS
• Pregnancy and Reproductive Issues
• Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis
• Disease-modifying Therapies for MS

Parkinson's Disease

• Parkinson’s Disease Fact Sheet
• The On-Off Phenomenon
• On-Off Phenomenon: When Levodopa Stops Working as Well

Stroke

• A Patient Guide to Understanding Strokes of Unknown Cause
  
• 2019 Updated Healthcare Professional Guide Understanding Diagnosis and Treatment of Cryptogenic Stroke
  
• RESPECT Trial- Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
• REDUCE Trial- Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
• Reducing Door-to-Needle Times using Lean Principles
• Implementation of Telemedicine Within Stroke Systems of Care
• Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke
• Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department
• Optimizing Stroke Systems of Care
• Effect of Telestroke on Emergent Stroke Care and Outcomes
• TeleStroke Simulation Video
• Know the Signs and Symptoms of a Stroke - Patient Handout
• American Heart Association / American Stroke Association Guidelines for the Primary Prevention of Stroke
• Recognize Warning Signs of a Stroke (Act FAST)
• Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke
• American Academy of Neurology practice advisory update: Patent foramen ovale and secondary stroke prevention
• REDUCE trial: Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
• Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials
• CLOSE trial: Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

Obesity

• Physical Activity Guidelines for Americans
• Prescription Medications to Treat Overweight and Obesity
• Bariatric Surgery: Patient Materials
• 2021 Obesity Algorithm®
• The Genetics of Human Obesity
• STOP Obesity Alliance - WHY WEIGHT? A Guide to Discussing Obesity & Health with Your Patients
• Neurobiology of food intake in health and disease
• Management of Obesity
• Healthy Meal Ideas
• Healthy Snack Guide
• Internet Tracking Tools for the Bariatric Patient
• Some Myths about Nutrition & Physical Activity
• American Board of Obesity Medicine (ABOM)
• Complementary and Alternative Medicine for the Treatment of Obesity
• AHA/ACC/TOS Treatment Algorithm - Chronic Disease Management Model for Primary Care of Patients with Overweight and Obesity
• How To Manage Your Weight Without Being Hungry - Patient Handout
• How To Use Fruits and Vegetables - Patient Handout
• How To Avoid Portion Size Pitfalls To Help Manage Your Weight - Patient Handout
• Rethink Your Drink - Patient Handout
• Childhood Obesity Facts

Ophthalmology

Age-related Macular Degeneration (AMD)

• Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR
• Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
• Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
• End of Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
• Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
• Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
• Abicipar pegol—a novel anti-VEGF therapy with a long duration of action
• Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
• Use and Safety of brolucizumab
• Phase III ARCHWAY study results
• Intravitreal Aflibercept for AMD: 2-year Results
• What AREDS means for you?
• Addressing the Anti-VEGF Treatment Burden
• Study of Safety and Efficacy of Brolucizumab
• ICD-10 Decision Tree: AMD
• Mayo Clinic: Dry Macular Degeneration
• American Academy of Ophthalmology Preferred Practice Patterns for AMD
• Understanding Your AMD - Patient Handout
• Protecting Eye Health and Possibly Reducing Risk for Developing Macular Degeneration - Patient Handout
• Research progress about the effect and prevention of blue light on eyes
• The Good and Bad of Retinal Fluid
• Review of Neovascular Age-Related Macular Degeneration Treatment Options
• Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review.
• Results from the Randomized Phase 2 Ladder Clinical Trial
• Results from the Phase 3 HAWK and HARRIER Studies
• Faricimab Demonstrates Durable Ang-2, VEGF Suppression
• Age-Related Macular Degeneration (AMD) Data and Statistics – Patient Education
• Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

Cataract and/or Refractive Surgery

• Intraoperative and postoperative pain in cataract surgery
• Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery
• Does Cataract Surgery Hurt?
• Strategies for Preventing Intraoperative Miosis
• Cataract and Refractive Lens Exchange Questionnaire
• Post-Refractive IOL Calculator
• Cataract in the Adult Eye Preferred Practice Pattern
• American Academy of Ophthalmology Task Force Consensus Statement for Extended Depth of Focus Intraocular Lenses
• American Society of Cataract and Refractive Surgery
• Physician Quality Reporting System Measures Associated with Cataract Surgery
• Toric IOL Calculator
• Preparing for Cataract Surgery - Postoperative Concerns - Patient Handout
• Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery

Conjunctivitis

• CDC - About Conjunctivitis (Pink Eye)

Diabetic Eye Disease

• What’s Next for Bispecific Antibody Faricimab
• Early intervention with Aflibercept has positive results in PANORAMA trial
• Digital Algorithmic Diabetic Retinopathy Severity Scoring System
• Diabetic Macular Edema—Personalizing Treatment
• Facts About Macular Edema
• Key Points From the Phase 3 PANORAMA Study
• Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY)
• Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
• Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression
• ICD-10 Decision Tree: Diabetes
• What Is Diabetic Retinopathy? – Patient Materials
• Aflibercept, Bevacizumab, or Ranibizumab for DME: Two-year Results
• American Optometric Association Evidence-Based Clinical Practice Guideline: Eye Care of the Patient with Diabetes Mellitus
• Diabetic Retinopathy Clinical Research Network Publications
• Understanding How Diabetes Can Affect Your Vision and Cause Diabetic Macular Edema - Patient Handout
• Understanding Diabetic Retinopathy - Patient Handout
• Study tracks clinical use of dexamethasone implant for DME
• The Mechanism of the Bispecific Antibody Faricimab
• What Is Diabetic Retinopathy?
• Diabetic Retinopathy Preferred Practice Patterns 2019

General

• Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
• Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
• ICD-10-CM for Ophthalmology
• EyeNet Magazine
• National Institutes of Health Guidelines on Human Subjects Research
• Eye Health Tips - Patient Handout
• AAO Preferred Practice Patterns
• American Academy of Ophthalmology. Teleophthalmology: how to get started.
• Centers for Medicare and Medicaid Services. Medicare telemedicine health care provider fact sheet.
• Vicchrilli S. Savvy coder: telemedicine during the public health emergency.
• AAO.org: Home Eye Test for Adults

Glaucoma

• A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
• Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
• National Eye Institute: Glaucoma
• Advances in medical therapy for glaucoma
• New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
• Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
• Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
• 2 Year Experience with Latanoprostene Bunod in Clinical Practice
• Sustained-release drug delivery systems for the treatment of glaucoma
• Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
• Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study
• A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
• Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
• Advances in medical therapy for glaucoma
• New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
• Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
• Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
• 2 Year Experience with Latanoprostene Bunod in Clinical Practice
• Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
• Prospective Study of NCX 470 for IOP Lowering: Phase 2 Clinical Results
• Advances in medical therapy for glaucoma
• New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
• Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
• Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
• Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
• Bimatoprost Implant. Prescribing Information
• Netarsudil and Latanoprost Ophthalmic Solution Prescribing Information
• A Review of Nitric Oxide for the Treatment of Glaucomatous Disease
• Surgical Innovations in Glaucoma
• Microinvasive Glaucoma Surgery (MIGS)
• Xen Gel Stent: Directions for Use
• Netarsudil Prescribing Information
• Latanoprostene Bunod Prescribing Information
• International Glaucoma Association
• American Glaucoma Society
• Take this Eye-Q Test - Patient Handout
• Don't Lose Sight of Glaucoma - Patient Handout
• What You Need to Know About Glaucoma - Patient Handout
• Videographic Assessment of Glaucoma Drops Instillation
• ICD-10 Glaucoma Reference Guide
• Facts About Glaucoma

Macular Disorders

• Management Recommendations for Macular Hole
• Revised Definitions from the International Classification of Diseases of the Vitreomacular Interface
• Understanding Vitreomacular Traction Syndrome - Patient Handout
• Managing Challenging Macular Holes

Ocular Surface Disease

• The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares
• New strategies for the management of ocular surface disease in glaucoma patients
• Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
• Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study
• Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies
• Neurostimulation in dry eye disease-past, present, and future
• Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
• Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
• A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
• Diseases of Ocular Surface
• Dry Eye: Patient Information
• Facts About Dry Eye
• TFOS DEWS II Definition and Classification Report
• American Academy of Ophthalmology Preferred Practice Patterns: Dry Eye Syndrome
• Care of the Patient with Ocular Surface Disorders
• American Academy of Ophthalmology Preferred Practice Patterns: Blepharitis
• Sjögren’s Syndrome Foundation

Presbyopia

• Potential new presbyopia treatments in development
• What Is Presbyopia? (Patient Material)
• Presbyopia Treatment (Patient Material)
• A Review of Pharmacological Presbyopia Treatment
• Treatments for presbyopia coming soon

Retinal Vascular Diseases (RVO)

• ICD-10 Decision Tree: Vein Occlusion
• Understanding Your Retinal Vein Occlusion (RVO) - Patient Handout
• Retinal Vein Occlusions Preferred Practice Patterns

Vitreoretinal Surgery

• Avoiding and Managing Complications of Vitreoretinal Procedures
• Preparing for a Vitrectomy - Patient Handout
• Advances in Vitreoretinal Surgery

Uveitis

• Preparing for Your Appointment - Patient Handout
• Uveitis Guidelines: Immunomodulatory Therapy
• Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
• MUST Study 7-Year Results
• Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III

Thyroid Eye Disease

• Graves’ Ophthalmopathy
• Review Article: Graves’ Disease
• Graves’ Eye Disease: Patient Information from the American Thyroid Association
• Graves' Disease: Patient Information
• Teprotumumab for the Treatment of Active Thyroid Eye Disease

Orthopedics

• Characteristic Types of Pain Following Total Knee Arthroplasty
• Diagnostic Algorithm for the Assessment of Patients Suffering from Pain Following Total Knee Arthroplasty

Pain Management

• CDC Guideline for Prescribing Opioids for Chronic Pain— United States, 2016

Substance Use Disorders

• Medication-Assisted Treatment Using Buprenorphine

Pediatrics

Ear, Nose and Throat Conditions

• Improving the Diagnosis of Acute Otitis Media: “Seeing Is Believing”
• FDA Drug Safety Communication: New warnings about using general anesthetics and sedation drugs in young children
• FDA Drug Safety Communication: FDA approves label changes for use of general anesthetic and sedation drugs in young children
• SmartTots
• General Anesthesia Study (GAS) Trial
• Anesthesia & Neurodevelopment Assessment (PANDA) study
• Clinical Practice Guideline: Tympanostomy Tubes in Children
• Tympanostomy Tube Placement in Children Using a Single-Pass Tool with Moderate Sedation
• Hummingbird TTS. Instructions for Use
• Ear Tubes in Pediatric Patients: Get the Facts – Educational Tool for Parents

Gastroenterology

• Persistent Diarrhea: A Clinical Review
• Cryptosporidiosis
• Giardiasis
• For Parents: Treating Pediatric Dehydration
• Swimming Pool Hygiene
• Children’s Health
• GI Kids

MRI with gadolinium contrast media

• FDA Drug Safety Communication: Gadolinium-based contrast agents for MRIs
• Information on Gadolinium-Based Contrast Agents
• NIH Perspective on Reports of Gadolinium Deposition in the Brain
• American Guidelines ACR/ASNR Position Statement on Use of Gadolinium Contrast Agents

Psychiatry

• Symptoms and Diagnosis of ADHD

Vaccine-preventable Diseases

• Recommendations for Prevention and Control of Influenza in Children, 2020–2021
• Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men
• Gardasil 9 Expanded for Patients Aged 27-45 Years Old
• HPV Vaccination: What Everyone Should Know
• HPV Infection Guidelines
• CDC HPV Vaccine Recommendations
• ACIP Recommendations for HPV Vaccination
• CDC’s HPV Resources and Tools for your Office
• Standing Order for HPV Vaccine
• Centers for Disease Control and Prevention HPV Vaccine Recommendations
• Recommended Immunization Schedule for Persons Aged 0 Through 18 Years (United States, 2017) – Educational Tool for Clinicians and Nurses
• Why Are Childhood Vaccines So Important? – Educational Tool for Parents

Pharmacy

Biosimilars

• State Laws and Legislation Related to Biologic Medications and Substitution of Biosimilars
• Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product
• Pharmacist Substitution of Biological Products: Issues and Considerations

Psychiatry

Binge Eating Disorder (BED)

• Weight Stigma in the Practice of Psychotherapy for Binge Eating Disorder: Guidance for Professionals
• Weight Stigma in Kids’ Programs and Schools: Guidance for Kids’ Programs Leaders
• DSM-5 Criteria for Binge Eating Disorder NOTE: This tool is best viewed in Google Chrome or Internet Explorer
• Binge Eating Disorder (BED) - A Comorbid Conundrum
• Binge Eating Disorder Resources

Bipolar Disorder

• Bipolar Disorder Diagnosis and Treatment for Patients
• Treatment of Bipolar Depression in Children and Adolescents
• Understanding Bipolar Depression - Patient Handout

Depression

• BPRS Brief Psychiatric Rating Scale
• PHQ-9 Quick Depression Assessment
• Montgomery-Asberg Depression Rating Scale
• Edinburgh Postnatal Depression Scale
• Depression - stopping your medicine – Patient Handout
• Major Depressive Disorder – Patient Handout
• What are the Causes of Depression? - Patient Handout

Mood Disorders

• Protocol for the Treatment of Agitation

Parkinson’s Disease Psychosis

• New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges
• Parkinson’s Disease Psychosis: Symptoms, Management, and Economic Burden

Schizophrenia

• New Second-generation Antipsychotics
• Long-acting Injectable Second Generation Antipsychotics
• Examples of Neurocognitive Assessments that Can Be Completed at the Bedside
• Motivational Interviewing: A tool to improve medication adherence?
• Living with Schizophrenia - Patient Handout
• Antipsychotics Fact Sheet - Patient Handout
• Support Groups and Supportive Resources - Patient Handout
• Approach to Schizophrenia Management At-A-Glance - Patient Handout
• Schizophrenia: Recognizing the Symptoms and Getting Treatment - Patient Handout

Substance Use Disorders

• Providers’ Clinical Support System for Opioid Therapies (PCSS-O): Educational Resources
• Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
• Opioid Treatment Program (OTP) Certification
• Medication Assisted Treatment (MAT) Certification

Tardive Dyskinesia

• Abnormal Involuntary Movement Scale exam
• Tardive Dyskinesia for Patients and Families
• Valbenazine Prescribing Information
• Deutetrabenazine Prescribing Information

Pulmonology

• Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
• Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
• Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
• Pulmonary rehabilitation
• European Respiratory Society/ American Thoracic Society Walking Test Guidelines
• Pulmonary Fibrosis Foundation Educational Resources

Interstitial Lung Disease

• Effect of continued treatment with pirfenidone (Nathan SD, et al. Thorax. 2016;71:429-435.)
• Nintedanib Prescribing Information
• Pirfenidone Prescribing Information
• Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
• Diagnosis of IPF: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
• Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
• American Thoracic Society Patient Resources on Interstitial Lung Disease
• Pulmonary Fibrosis Foundation Patient Education Materials
• Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
• Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
• Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
• Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study
• Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
• Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
• Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials

Non-Tuberculous Mycobacteria

• Learn about NTM Lung Disease
• ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
• Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
• “INSIGHT” A Patient’s Perspective on NTM
• CDC Clinician Resources on NTM Infection
• Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease
• Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
• Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study
• NORD Nontuberculous Mycobacterial Lung Disease Patient and Family Resources

Sarcoidosis

• Repository corticotropin for Chronic Pulmonary Sarcoidosis

Rheumatology

General

• Upadacitinib Prescribing Information
• Risankizumab Prescribing Information
• Guselkumab Prescribing Information
• ACR COVID-19 Clinical Guidance for Adult Patients with Rheumatic Diseases
• ACR COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases

Biosimilars

• Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
• Biosimilars: implications for rheumatoid arthritis therapy.
• The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
• Clinical trials of biosimilars should become more similar.
• Biosimilars: More Treatment Options Are on the Way
• FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
• Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
• Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Gout

• Treat to target in gout
• 2020 American College of Rheumatology Guideline for the Management of Gout
• 2016 updated EULAR evidence-based recommendations for the management of gout
• Pegloticase Prescribing Information
• Pegloticase treatment of chronic refractory gout: Update on efficacy and safety
• Gout Patient fact Sheet
• Moving the Needle: Improving the Care of the Gout Patient

Immune-mediated adverse reactions

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Clinical Practice Guideline
• The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy
• Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
• Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
• Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
• Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

Psoriatic Arthritis

• Psoriatic Arthritis – Disease Primer
• Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
• JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis
• 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
• EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
• Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
• Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
• Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

Spondyloarthritis

• JAK1 selective inhibitors for the treatment of spondyloarthropathies
• Axial spondyloarthritis: new advances in diagnosis and management
• TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases
• From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
• 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
• Recognizing Axial Spondyloarthritis: A Guide for Primary Care
• Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
• Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
• JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
• Pain in Axial Spondyloarthritis: More to It Than Just Inflammation
• Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities
• Spondylitis Association of America: Resources and Support
• Spondyloarthritis Patient Fact Sheet
• What Is Axial Spondyloarthritis (AxSpA)?
• Recommendations for the Treatment of Ankylosing Spondylitis
• 2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
• Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
• Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
• Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

Juvenile Idiopathic Arthritis (JIA)

• ACR Update of Recommendations to the Treatment of JIA
• What is JIA? - Patient Handout

Lupus

• 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
• 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
• Lupus Foundation of American Caregiver Toolkit
• Patient Fact Sheet: Lupus
• Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus
• Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
• Lupus Foundation of American Caregiver Toolkit
• Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
• Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments
• Phase 3 AURORA study of voclosporin versus standard of care in lupus nephritis
• Belimumab prescribing information
• Voclosporin prescribing information

Rheumatoid Arthritis (RA)

• 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
• RA and Vaccinations
• RA Treat-to-Target Recommendations
• The Purple Book for Biosimilars
• 2015 ACR Guideline for the Treatment of RA
• RA Overview (for Patients)
• RA Treatment (for Patients)
• EULAR Recommendations Update: Management of RA
• Recent advances in the treatment of rheumatoid arthritis

Systemic Sclerosis

• 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
• Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
• Pulmonary Fibrosis in Systemic Sclerosis: Diagnosis and Management

Vasculitis

ANCA-Associated Vascilitis

• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
• ANCA-Associated Vasculitis
• EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
• Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
• Vasculitis Foundation: Eosinophilic Granulomatosis With Polyangiitis
• NIH Genetic and Rare Diseases Information Center: Eosinophilic Granulomatosis With Polyangiitis
• American College of Rheumatology Churg-Strauss Syndrome Classification Criteria
• National Organization for Rare Disorders: Churg Strauss Syndrome

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

• Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
• Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management
• Vasculitis Foundation: Eosinophilic Granulomatosis With Polyangiitis
• NIH Genetic and Rare Diseases Information Center: Eosinophilic Granulomatosis With Polyangiitis
• American College of Rheumatology Churg-Strauss Syndrome Classification Criteria
• National Organization for Rare Disorders: Churg Strauss Syndrome
• American College of Rheumatology Churg-Strauss Syndrome Classification Criteria
• National Organization for Rare Disorders: Churg Strauss Syndrome

Giant Cell Arteritis

• Giant Cell Arteritis – Fast Facts for Patients
• Giant Cell Arteritis – Vasculitis Foundation
• ACR Classification of Giant Cell Arteritis
• Recognition and Management of Giant Cell Arteritis
• GIACTA Trial of Tocilizumab in Giant Cell Arteritis
• Giant Cell Arteritis